Niranjan Sardesai
President & Chief Executive Officer Geneos Therapeutics
Dr. Sardesai is Chief Executive Officer & President of Geneos Therapeutics, a Phase 2 clinical stage biopharmaceutical company focused on personalized immunotherapies for cancer. His expertise spans broad aspects of biopharmaceutical development particularly as related to infectious disease vaccines and cancer immunotherapies.
Dr. Sardesai received his PhD in Chemistry from the California Institute of Technology and MBA from the Wharton School of the University of Pennsylvania. He was awarded fellowships at the Scripps Research Institute and the Massachusetts Institute of Technology (MIT). Dr. Sardesai received his Bachelor and Master of Science degrees in Chemistry from the Indian Institute of Technology, Mumbai. Dr. Sardesai has authored over 120 peer-reviewed manuscripts and has been granted multiple patents.
Seminars
- Reviewing clinical data in advanced liver cancer and adjuvant GBM patients demonstrating the safety, immunogenicity, and efficacy of Geneos’ personalized vaccine platform
- Exploring how patient-specific neoantigen targeting can enhance anti-tumor immunity across multiple solid tumor indications
- Discussing the implications of these findings for personalized cancer vaccines in advanced and adjuvant cancer treatment settings
